Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leucovorin for 5q Minus Syndrome
NCT00004997Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Apr 1998
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of folinic acid in Myelodysplastic Syndrome Associated With Isolated Deletion of Chromosome 5q (MDS-del(5q)), sponsored by National Institutes of Health. Primary endpoint: Normalization of hematopoietic cell growth and differentiation. Started Apr 1998; status: completed.
02
Drugs
folinic acid
03
Conditions
Myelodysplastic Syndrome Associated With Isolated Deletion of Chromosome 5q (MDS-del(5q))
Beyond the preview
Go deeper on NCT00004997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004997.